



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Dorsomorphin

Chemical Properties

CAS No. :	866405-64-3
Formula:	C ₂₄ H ₂₅ N ₅ O
Molecular Weight:	399.49
Appearance:	no data available
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year



Biological Description

Description	Dorsomorphin (BML-275) is an AMPK inhibitor (K _i =109 nM) that is selective and ATP-competitive. Dorsomorphin inhibits the BMP type I receptors ALK2, ALK3, and ALK6. Dorsomorphin induces autophagy, and possesses antitumor activity.
Targets(IC50)	AMPK, Autophagy, TGF-beta/Smad
In vitro	<p>METHODS: Human tumor cells HeLa and HCT116 were treated with Dorsomorphin (1.25-80 μM) for 24 h, and cell viability was measured by CCK-8.</p> <p>RESULTS: Dorsomorphin inhibited the viability of HeLa and HCT116 cells with IC₅₀ values of 10.71 μM and 11.34 μM, respectively. [1]</p> <p>METHODS: ATL patient-derived PBMCs cells were treated with Dorsomorphin (5-25 μM) for 24 h. Apoptosis was detected by Flow Cytometry.</p> <p>RESULTS: Dorsomorphin increased the frequency of early apoptotic cells in PBMCs from patients with acute and chronic forms of ATL in a dose-dependent manner. [2]</p>
In vivo	<p>METHODS: To test the antitumor activity in vivo, Dorsomorphin (10 mg/kg) was administered intraperitoneally to NOD/SCID mice bearing human tumor S1T once daily for 28 days.</p> <p>RESULTS: Dorsomorphin inhibited the growth of human ATL tumor xenografts in NOD/SCID mice. [2]</p> <p>METHODS: To examine the effect on SMAD activity in vivo, Dorsomorphin (10 mg/kg) was administered as a single intraperitoneal injection to iron-dextran-treated C57BL/6 mice.</p> <p>RESULTS: Dorsomorphin eliminated iron-dextran-induced iron-mediated increase in hepatic SMAD1/5/8 phosphorylation. [3]</p>
Kinase Assay	HT1080 cells are seeded in 24-well plates (2×10 ⁴ cells per well) and treated with Dorsomorphin in the presence or absence of glucose or 10 mM 2DG for 2 h. HT1080 cells that overexpressed the wild-type and dominant negative AMPKα1 are prepared by transfecting plasmid DNA (pAMPKα1-wt, pAMPKα1-D168A and pcFlag as a control) in 6-well plates, seeding in 24-well plate and treating with UPR inhibitors. Cells are lysed with cell lysis buffer (20 mM Tris-HCl, pH 7.5, 250 mM NaCl, 10% glycerol, 0.5% NP-40, 1 mM EDTA, 1 mM EGTA, 0.2 mM PMSF, 1 μg/mL pepstatin, 0.5 μg/mL leupeptin, 5 mM NaF, 2 mM Na ₃ Vo ₄ , 2 mM β-glycerophosphate, 1 mM DTT). Relative AMPK kinase activity (mean±SD of duplicate determinations) to control sample (vehicle or pcFlag under normal growth conditions) is determined using the CycLex AMPK kinase assay kit[2].

Cell Research	Dorsomorphin is dissolved in DMSO (10 mM) and stored, and then diluted with appropriate media (DMSO 0.5%) before use[2]. HeLa and 786-O cells are treated with various concentrations of Dorsomorphin (0, 0.3, 1, 3, 10 μ M), Versipelostatin and Phenformin in the presence or absence of 10 mM 2DG or 1 μ g/mL of Tunicamycin as a stressor for 30 h in 96-well plates. For the combination study, 786-O cells are treated with various concentrations of UPR inhibitors in the presence or absence of 10 mM 2DG for 24 h. The medium is then replaced with fresh growth medium, and cells are cultured for a further 15 h. Subsequently, MTT is added to the culture medium, and the absorbance of each well is determined. For the viability assay under glucose-withdrawal conditions, HT1080 cells are treated with various concentrations of Dorsomorphin and phenformin in 12-well plates in the presence or absence of glucose for 18 h, seeded in 96-well plates with growth medium, and then cultured for a further 48 h before MTT is added. Relative cell survival (mean \pm SD of quadruplicate determinations) is calculated by setting each control absorbance from untreated cells as 100%. The effects of drug combinations at concentrations producing 80% cell growth inhibition (IC80) are analyzed using the isobologram method[2].
---------------	---

Solubility Information

Solubility	DMSO: 1.33 mg/mL (3.34 mM), Sonication and heating are recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.5032 mL	12.516 mL	25.0319 mL
5 mM	0.5006 mL	2.5032 mL	5.0064 mL
10 mM	0.2503 mL	1.2516 mL	2.5032 mL
50 mM	0.0501 mL	0.2503 mL	0.5006 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Wang X, Hu W, Qu L, et al. Tricin promoted ATG-7 dependent autophagic degradation of α -synuclein and dopamine release for improving cognitive and motor deficits in Parkinson's disease. Pharmacological Research.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 36 Washington Street, Wellesley Hills, MA 02481